J & J and Eli Lilly halts Covid-19 drug trial


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ J & J and Eli Lilly halts Covid-19 drug trial
ELI Lilly, J & J and AstraZeneca halts covid drug trials

Pharmaceutical giant Johnson & Johnson announced on Monday the suspension of its clinical trial of a vaccine against COVID-19 after one of the participants fell ill.

"We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the entire Phase 3 trial, due to unexplained illness in one participant," the group said in a statement.

The company didn't reveal the nature of the person's illness. “We must respect this participant’s privacy,” the statement said.“We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.”


The company's current protocols provide for the suspension of a study to determine whether the illness, in this case, is related to the drug being evaluated and whether the trial can be resumed. Because of the trial's suspension, recruitment for participants for phase 3 testing has also been frozen.

Recruitment of volunteers for phase 3 of the Johnson & Johnson clinical trials began at the end of September, with the aim of enrolling 60,000 participants at more than 200 sites in the United States and other countries, the group and the US National Institutes of Health (NIH) announced.

Trials were also taking place in Argentina, Brazil, Chile, Colombia, Mexico, Peru and South Africa.

Johnson & Johnson is one of four companies in advanced stages of trialling a vaccine for coronavirus and was due to publish its results early next year.

The United States granted some $1.45 billion (€1.2 billion) in financing to the company as part of Operation Warp Speed, the White House's initiative to speed up the development and production of a viable COVID-19 vaccine.


Its candidate vaccine is based on a single dose of an adenovirus, which is responsible for the common cold and has been modified so that it cannot replicate, combined with a part of the Sars-CoV-2 coronavirus called the spike protein (or "spike") that it uses to penetrate human cells.

Johnson & Johnson used the same technique for its Ebola haemorrhagic fever vaccine, which was approved for marketing by the European Commission in July.

Pausing clinical trials because of illness is not uncommon.

In September, trials of the COVID-19 candidate vaccine developed by AstraZeneca and Oxford University, considered one of the most promising, were also halted after a UK participant developed an unexplained pathology.

The trials resumed in the UK and Japan in early October but haven't yet restarted in the United States.

US pharmaceutical firm Eli Lilly on Tuesday suspended its Phase 3 trial of its lab-produced antibody treatment in hospitalized patients over an unspecified incident.

Story Credit :  https://www.euronews.com/ 

Tags : #ELILilly #JohnsonJohnson #Astrazeneca #Covid-19DrugTrials #Regeneron #Ebola #USNIH

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026